FENTANYL TRANSMUCOSAL (ABSTRAL, ONSOLIS)

Course overview

FentaNYL transmucosal is U.S. FDA-approved to treat breakthrough pain in opioid-tolerant cancer patients ≥ 18 years (≥ 16 years for Actiq) already receiving around-the-clock opioid treatment for underlying pain. This continuing education module is designed to give the reader/learner an increased understanding of fentanyl transmucosal. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.